MITOZYTREX Drug Patent Profile
✉ Email this page to a colleague
When do Mitozytrex patents expire, and when can generic versions of Mitozytrex launch?
Mitozytrex is a drug marketed by Supergen and is included in one NDA.
The generic ingredient in MITOZYTREX is mitomycin. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the mitomycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mitozytrex
A generic version of MITOZYTREX was approved as mitomycin by HIKMA on April 19th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MITOZYTREX?
- What are the global sales for MITOZYTREX?
- What is Average Wholesale Price for MITOZYTREX?
Summary for MITOZYTREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,437 |
| DailyMed Link: | MITOZYTREX at DailyMed |
Recent Clinical Trials for MITOZYTREX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| City of Hope Medical Center | Phase 2 |
| ECOG-ACRIN Cancer Research Group | Phase 2 |
| Mayo Clinic | Phase 2 |
US Patents and Regulatory Information for MITOZYTREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supergen | MITOZYTREX | mitomycin | INJECTABLE;INJECTION | 050763-001 | Nov 14, 2002 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
